Clinical Trials Directory

Trials / Terminated

TerminatedNCT01931709

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Quantitative Dynamic PET and MRI and Breast Cancer Therapy

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Detailed description

PRIMARY OBJECTIVES: I. To determine whether detailed kinetic analysis of FDG PET and magnetic resonance (MR) imaging studies for measures of tumor metabolism and blood perfusion can predict response and outcome for breast cancer patients undergoing neo-adjuvant therapy. II. To compare the in vivo tumor biology associated with responsive and resistant tumors as measured by kinetic changes in FDG PET and MR imaging parameters to tumor subtypes analyzed from assay of pre-therapy biopsy and post-therapy surgical tissue. OUTLINE: Patients undergo FDG PET and DCE-MRI 1-2 weeks before prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).

Conditions

Interventions

TypeNameDescription
RADIATIONfludeoxyglucose F 18Undergo FDG PET
DEVICEpositron emission tomographyUndergo FDG PET
DEVICEdynamic contrast-enhanced magnetic resonance imagingUndergo DCE-MRI
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2011-11-01
Primary completion
2016-02-01
Completion
2022-10-26
First posted
2013-08-29
Last updated
2023-11-18
Results posted
2017-06-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01931709. Inclusion in this directory is not an endorsement.